GeoVax Labs CEO David Dodd talks to Proactive about its three separate ongoing Phase II clinical trials in developing a COVID-19 booster to mRNA vaccines, a COVID-19 vaccine to immunocompromised patients, and and a cancer immunotherapy for advanced head and neck cancer. Dodd says each are progressing well, and he says, the company is currently funded until the second quarter of 2023.
GeoVax Labs updates investors on its COVID-19 vaccine and cancer immunotherapy clinical trials
